02/09/2025
A Billion People, Ten Minutes, One Platform: The Case for Doppler Labs' At-Home Hearing: Netcapital Raise Ends November 14, 2025 | Dr. Kirk Adams
https://drkirkadams.com/doppler-labs-at-home-hearing/
Here Dr. Kirk Adams lays out a plain case: move clinical-grade hearing from the clinic to the home and you remove the bottlenecks that keep people from hearing the moments that matter. He frames the unmet need, 1.5 billion people worldwide, high costs, too many devices in drawers, and explains why Doppler's at-home platform is different: clinical-grade hearing aids in three styles paired with Jenn, a handheld tablet that tunes in five to ten minutes, saves up to eight profiles, and is backed by accessories, 24/7 chat, and extended phone support. Pricing is simple ($199 down + $29/month after a trial, with worn-out devices replaced for subscribers), and the model is built for stickiness where life happens, at home, at work, on the go.
He then connects go-to-market to equity: direct-to-consumer, big-box retail like Walmart and Walgreens, and special channels such as the VA and international partnerships. Leadership and milestones are in place (experienced executives, four issued utility patents, completed clinical trials, beta hardware/software, supply chain and pricing locked in), risks are acknowledged with clear mitigations, and a nonprofit arm will take the same technology to regions with few or no audiologists. The call to action is immediate: invest or share the raise on Netcapital, Common Stock under Reg CF at $8 per share, $104 minimum, before 11:59 p.m. ET on November 14, 2025, and help bring hearing home: https://netcapital.com/companies/doppler-labs.